News ReleaseFor Immediate Release |
 |
Investor Contact (Merge):
Julie Pekarek
Chief Marketing Officer
414.977.4254
ir@merge.com
ETRIALS WORLDWIDE INTRODUCES NEW ECLINICAL CAPABILITIES AT DIA'S 45TH ANNUAL MEETING IN SAN DIEGO
Morrisville, NC, June 22, 2009 – etrials Worldwide, Inc. (Nasdaq: ETWC), a leading provider of adaptive eClinical solutions , today announced it is launching several of its newest eClinical capabilities, including three new eDiary devices, an all access portal environment and an on demand data export tool at this week's Drug Information Association (DIA) Annual Meeting in San Diego, Calif.
Adding three Windows-based eDiary devices, grows etrials' customer device options for electronic patient reported outcomes to four, including three touch screen PDAs and a ruggedized PDA phone, operating on enhanced software functionality allowing customers to tailor their eDiary solution to study requirements and budgets.
With the etrials Portal, customers gain the ability to access each of etrials' eClinical applications -- including its electronic data capture (EDC), integrated Web interface (IWR) administrative Web interface for drug supply and randomization and eDiary data -- all from a single username and password sign-on portal environment. Therein, a host of portlets provide customized dashboard views and enable the seamless toggle between studies and eClinical solutions.
The etrials' Data Exports on Demand tool puts the control back into the hands of clinical operations and biostatisticians by allowing them to export study data when they want it and how they want it. Accessible directly within the etrials portal, it allows users to instantly download of SAS datasets,CSV files and/or Microsoft Access database fileswith the click of a button.
"etrials' latest capabilities are an extension of our best-of-breed eClinical solutions suite designed to help make the clinical trial process smarter," said M. Denis Connaghan, Chief Executive Officer of etrials Worldwide. "Each of these new developments focus on enhancing integral parts of the clinical data management process and clearly provide research sponsors and contract research organizations with a more efficient, compliant and cost effective way to manage their clinical trials."
etrials' Three New eDiaries, All Access Portal and Data Exports on Demand, among other new capabilities will be demonstrated in San Diego, Calif., at the DIA's 45 Annual Meeting, booth #1321.
This news release contains "forward-looking statements," including statements which are related to future, not past, events. Forward-looking statements usually describe expected future business and financial outlook or performance, and often contain words such as “will,” “believes,” “intends,” “anticipates,” “expects,” "plans," "seeks," “see” and similar expressions. Forward-looking statements, by their nature, address matters that are, to varying degrees, uncertain and subject to various known and unknown risks. Such forward-looking statements include Merge’s and etrials’ decision to enter into an agreement for Merge to acquire etrials, the ability of the parties to complete the transaction contemplated by the merger agreement, including the parties’ ability to satisfy the conditions set forth in the merger agreement, and the possibility of any termination of the merger agreement. For Merge, particular uncertainties and risks that could cause actual results to differ materially from post-merger forward-looking statements include: the consummation and the successful integration of etrials into Merge; market acceptance and performance of its products and services; the impact of competitive products and pricing; possible delays in the implementation of its managed services offering; the risks and effects of its recent changes in its executive and Board leadership; the risks and effects of its recent securities issues, including the issuance of certain senior secured notes; the past restatement of its financial statements and other actions that may be taken or required as a result of such restatement; its ability to generate sufficient cash from operations to meet future operating, financing and capital requirements, including repayment obligations with respect to its outstanding indebtedness; risks associated with its prior delays in filings with the SEC or its ability to continue to meet the listing requirements of The NASDAQ Stock Market; the costs, risks and effects of various pending legal proceedings and investigations, including the formal investigation being conducted by the Securities and Exchange Commission; and other risk factors detailed in its filings with the Securities and Exchange Commission. More information about potential factors which could cause etrials’ actual results to differ from the forward-looking statements included in this announcement is included in its filings with the Securities and Exchange Commission, including the “Risk Factors” Section of its Form 10-K filed on March 10, 2009. These uncertainties and risks may cause its actual future results to be materially different than those expressed in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. Neither Merge nor etrials undertakes any obligation to update such forward-looking statements or any of such risks, uncertainties and other factors.